Nuvation Bio Inc. Stock price

Equities

NUVB

US67080N1019

Biotechnology & Medical Research

Market Closed - Nyse 04:00:02 2024-02-22 pm EST 5-day change 1st Jan Change
1.77 USD -0.56% Intraday chart for Nuvation Bio Inc. -1.12% +17.22%
Sales 2023 * - Sales 2024 * - Capitalization 390M
Net income 2023 * -85M Net income 2024 * -105M EV / Sales 2023 * -
Net cash position 2023 * - Net cash position 2024 * - EV / Sales 2024 * -
P/E ratio 2023 *
-4.58 x
P/E ratio 2024 *
-3.75 x
Employees 53
Yield 2023 *
-
Yield 2024 *
-
Free-Float 72.78%
More Fundamentals * Assessed data
Dynamic Chart
1 day-0.56%
1 week+2.91%
Current month+9.26%
1 month+21.23%
3 months+42.74%
6 months+6.63%
Current year+17.22%
More quotes
1 week
1.71
Extreme 1.71
1.83
1 month
1.52
Extreme 1.52
1.83
Current year
1.43
Extreme 1.43
1.83
1 year
0.95
Extreme 0.95
2.13
3 years
0.95
Extreme 0.95
15.23
5 years
0.95
Extreme 0.95
15.23
10 years
0.95
Extreme 0.95
15.23
More quotes
Managers TitleAgeSince
Founder 66 18-03-19
Director of Finance/CFO 46 20-06-30
Chief Tech/Sci/R&D Officer 54 22-07-17
Members of the board TitleAgeSince
Founder 66 18-03-19
Director/Board Member 71 19-07-31
Director/Board Member 63 20-09-30
More insiders
Date Price Change Volume
24-02-22 1.77 -0.56% 401,216
24-02-21 1.78 0.00% 435,794
24-02-20 1.78 +2.89% 583,347
24-02-16 1.73 -3.35% 778,823
24-02-15 1.79 +4.07% 653,172

Delayed Quote Nyse, February 22, 2024 at 04:00 pm EST

More quotes
Nuvation Bio Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing differentiated and novel therapeutic candidates. Its proprietary portfolio includes mechanistically distinct oncology therapeutic product candidates, each targeting some of the difficult-to-treat types of cancer. The Company's clinical-stage product candidate, NUV-868, is a BD2-selective oral small molecule bromodomain and extra terminal (BET) inhibitor. NUV-868 inhibits the protein BRD4, a member of the BET family that epigenetically regulates a number of important proteins that control tumor growth and differentiation, including oncogenes such as c-myc. It has designed NUV-868 to reduce the therapeutic limiting toxicities of BRD4 inhibitors in development by optimizing BD2 versus BD1 selectivity. Its drug-drug conjugate (DDC) platform is a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies with parallels to Antibody-Drug Conjugates (ADCs).
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
1.77 USD
Average target price
3.725 USD
Spread / Average Target
+110.45%
Consensus
  1. Stock
  2. Equities
  3. Stock Nuvation Bio Inc. - Nyse
+229% on MICROSOFT CORPORATION since our purchase on January 11, 2019
Replicate our performance
fermer